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Abstract
There is an unambiguous association of Streptococcus gallolyticus infection with colorectal
cancer, although there is limited information about epidemiology or interaction between
molecular and environmental factors. We performed an original quantitative analysis of S.
gallolyticus in unselected colorectal cancer patients (n = 190) and their association with clini-
cal, pathological tumor molecular profiles (microsatellite instability, hypermethylator pheno-
type and chromosomal instability pathways), and other biological factors in colorectal tumor
and normal tissues (cytomegalovirus and Epstein-Barr virus infection). We developed a new
quantitative method to assess bacterial load. Analytical validation was reached with a very
high sensitivity and specificity. Our results showed a 3.2% prevalence of S. gallolyticus
infection in our unselected cohort of colorectal cancer cases (6/190). The average S. galloly-
ticus copy number was 7,018 (range 44–34,585). No previous reports relating to S. gallolyti-
cus infection have been published for unselected cohorts of patients. Finally, and despite a
low prevalence of S. gallolyticus in this study, we were able to define a specific association
with tumor tissue (p = 0.03) and with coinfection with Epstein-Barr virus (p = 0.042; OR:
9.49; 95% IC: 1.1–82.9). The prevalence data provided will be very useful in the design of
future studies, and will make it possible to estimate the sample size needed to assess pre-
cise objectives. In conclusion, our results show a low prevalence of S. gallolyticus infection
in unselected colorectal cancer patients and an association of positive S. gallolyticus infec-
tion with tumor tissue and Epstein-Barr virus coinfection. Further studies will be needed to
definitively assess the prevalence of S. gallolyticus in colorectal cancer and the associated
clinicopathological and molecular profiles.
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Introduction
Cancer is a multifactorial group of diseases generated by a combination of different genetic
and environmental factors. In the last decade we have experienced an exponential increase in
new knowledge about the molecular basis of the disease because of the availability of new tech-
nological tools for massive molecular analysis. Nevertheless, there is ample room for improve-
ment in the knowledge about the interaction between the molecular and environmental
factors. Colorectal cancer (CRC) is the leading cause of cancer in westernized countries
[1]. The main molecular features of CRC are well known, and a multistep process with a pro-
gressive accumulation of (epi)genetic alterations has been established as the route of carcino-
genesis. Three major molecular pathways of carcinogenesis have been defined for tumor
classification: microsatellite instability (MSI) group represented by 15% of CRC. This group
includes defective DNA mismatch repair with microsatellite instability (MSI) and POLE/
POLD1 mutations, containing multiple frameshifted genes and BRAFV600E and is character-
ized by hypermutated tumors [2]; chromosomal instability (CIN) group represented by 85% of
CRC. This is a non-hypermutated group with multiple somatic copy number alterations, and
aneuploidy by recurrent missegregation of whole chromosomes during cell division [3,4], con-
taining oncogenic activation of KRAS and PIK3CA and mutation and loss of heterozygosity
of tumor suppressor genes such as APC and TP53; and CpG Island Methylator Phenotype
(CIMP) CRCs in 20% that overlap greatly with MSI CRC and some non-hypermutated
CRC [2].
The main environmental factors linked with CRC are diet and the closely related factor of
the gut microbiota, including viruses. The gut microbiota is currently considered to be an
organ, and the symbiotic interactions between the gut microbiota and the digestive tract,
under the surveillance of the immune system, are essential for maintaining homeostasis. Any
disruptive imbalance can alter this particular ecosystem and promote diseases such as inflam-
matory bowel diseases and cancer [5]. Many changes in the relative bacterial content of the gut
have been described in CRC, suggesting a major role of dysbiosis in carcinogenesis. Among
the dysbiotic bacterial species identified and suspected to play a role in colorectal carcinogene-
sis are Streptococcus gallolyticus, Bacteroides fragilis, Enterococcus faecalis, Clostridium septicum,
Fusobacterium spp. and Escherichia coli [5]. Strikingly, however, Streptococcus gallolyticus
subsp. gallolyticus (SG; previously known as Streptococcus bovis biotype I) is one of the very
few opportunistic pathogens that has been clinically linked to malignant colonic diseases [6].
Regarding the role of viruses in CRC, a recent comprehensive screening for viruses using
next-generation sequencing data from The Cancer Genome Atlas (TCGA) demonstrated the
presence of viral sequences in CRC. Epstein–Barr virus (EBV), cytomegalovirus (CMV), and
human papillomavirus type 18 (HPV-18) are considered potential causes of CRC, although
their oncogenic role is yet to be established [7].
The results of a recent meta-analysis suggest an unambiguous association of SG infection
with CRC. It has been proposed that colonization of the colonic mucosa by this bacterium
could be a risk factor for CRC, although the nature of this association remains unknown [8].
There is a growing need to clarify whether it is cause or consequence and to provide informa-
tion about the possible mechanisms involved. Available data are scarce and few reports have
attempted a prevalence study of SG in unselected cases of CRC. In addition, there is limited
information about the tumor molecular profile of SG-positive CRC cases that could reveal
mechanistic clues for the potential role of SG in carcinogenesis, or alternatively, its oncomodu-
lator effect in specific molecular subtypes of CRC.
The present study addresses the following two questions: (i) what is the prevalence of SG in
tumor and normal mucosa from an unselected cohort of CRC patients, and (ii) what is the
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association, if any, of SG infection with clinical, pathological, molecular and other biological
variables of the colorectal tumors.
Materials and methods
Design and analytical validation of a quantitative real-time PCR assay for
S. Gallolyticus (SG) bacterial load
A collection of 76 isolated from bacteraemia from the Hospital General Universitario de Elche
(Spain) was used in the present study to obtain SG-positive controls. The strains were origi-
nally identified as Streptococcus bovis with the commercial kit API 20 Strep (bioMe´rieux,
Marcy l’Etoile, France). Strains were streaked onto chocolate agar plates and incubated at 37˚C
for 24 hours. One colony of each plate was selected and DNA was extracted using Chelex (Bio-
Rad, Hercules, California, USA) according to the manufacturer’s instructions. Specific PCR
primers for SodA gene were designed by the alignment of SodA gene sequences of S. infantar-
ius, S. lutetiensis and SG giving an amplicon of 419-bp size. Primers: sodA_F: YGATRCAGAAA
CAATGACATTDCA; sodA_R: ATTGRTTYYTTACCYTCTGA.PCR conditions: initial denatur-
ation step at 94˚C for 2 min; followed by 30 cycles of denaturation at 94˚C for 10 s, annealing
at 50˚C for 30 s, extension at 68˚C for 30 s, and a final extension step at 68˚C for 7 min. Ampli-
fication products were visualized in a 2% agarose gel. Sanger sequencing of the amplicons was
performed to confirm SG strains (Secugen. Madrid, Spain). Sequence homologies were estab-
lished by BLASTn (http://blast.st-va.ncbi.nlm.nih.gov/Blast.cgi). The SG-positive strains
were selected as positive controls. Next, primers and TaqMan probes for qPCR to amplify the
three subspecies of S. gallolyticus, specifically: S. gallolyticus subspp. gallolyticus, S. gallolyticus
subspp. pasteurianus and S. gallolyticus subspp. macedonicus were designed according to the
nucleotide sequences of SodA gene (Beacon Designer): Forward primer SG_F (5´-TGGCTC
ATTTGAYGAATT-3´), reverse primer SG_R (5´-GAGAGCACTTCAAGTTTG-3 )´ and probe
SG (5´-FAM-TTCATTCACCACAAGCCA-BHQ1-3´) were used for detection. Real-time PCR
reactions were prepared as follow: 12.5 μL of Universal PCR MasterMix (Applied Biosystems),
0.75 μL of 12.5 pmol/μL reverse and forward primers, 0.25 μL of probe 4 pmol/μL, 5 μL DNA
and RNase free water up to 25 μL of the total reaction volume. PCR cycling conditions were
95˚C for 10 min and 40 cycles of two steps of amplification (95˚C for 15 s and 60˚C for 1 min).
SG qPCR detection assays were run in triplicate.
Standard curves and the limit of detection were obtained by plotting the threshold cycle
value (Ct) obtained by a 10-fold serially diluted DNA against DNA copy number input. A stan-
dard curve was accepted when the slope was from –3.3 to –3.6. We used DNA from previously
confirmed positive controls of S. gallolyticus and diluted from 106−10 copies/μL. In addition,
to assess the specificity of the quantitative PCR system, 20 different isolates of confirmed SG
were analysed in triplicate. Reproducibility of results was assessed in independent validation
experiments.
Patients and specimens
A total of 380 samples derived from 190 patients (frozen tumor tissues and normal appearing
colonic mucosa for each patient) from the Hospital Provincial Castellon Biobank (Spain) were
included in this study. This is an unselected cohort of CRC patients who underwent surgery
with curative intention.
In addition to the patients’ biological samples, clinical and pathological information were
obtained from the Hospital Provincial Castellon Biobank. Written informed consent, for
inclusion in the Biobank was obtained from every participating individual. The study complied
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with the Declaration of Helsinki (2013) and was approved by the Ethics Committee of the
Elche University Hospital.
DNA was isolated from frozen colorectal normal and tumor tissues after mechanical
homogenization (Tissue Lyser; Qiagen, Valencia, CA). DNA isolation was performed using
the EZ1 DNA Tissue kit and the EZ1 BioRobot (Qiagen, Valencia, CA) according to the manu-
facturer’s instructions.
Detection and quantification of S. gallolyticus in normal colonic mucosa
and colorectal tumor tissues by qPCR
Quantitative assessment of SG in colorectal tissues was approached as described above. Fifty
nanograms of DNA from each tissue sample at 1ng/μL were tested. In addition, positive and
negative controls and a six-point standard curve (10–1,000,000 copies; Pearson’s correlation
coefficient > 0.98) were analysed together with the samples for each run. Cycle threshold (Ct)
values obtained by each sample were interpolated with the linear regression of the standard
curve for the quantification. All the samples were analysed in triplicate. Positive results were
considered when at least two of the replicates showed detectable bacterial load with more than
10 copies.
Demographic, clinical and pathological variables
Demographic (gender and age), clinical and pathological variables (tumor location and stage)
were collected as associated information from the Hospital Provincial Castellon Biobank.
Tumors located in the caecum through the splenic flexure were grouped together as proximal
colon cancers (P); tumors located in the descending, sigmoid colon, recto-sigmoid junction
and rectum, were classified together as distal colon cancer (D). Stage at diagnosis was classified
as I, II, III and IV [9].
CRC molecular variables
To attempt a tumor molecular classification, the main molecular hallmarks of the different
pathways were considered in the study. Therefore, CIMP phenotype and MSI status were
tested to group the tumors in three mayor pathways as follow: (i) Chromosomal instability
tumors were defined as microsatellite stable tumors and no hypermethylated phenotype; (ii)
Microsatellite unstable tumors were those with MSI, independently of the methylation status,
and (iii) tumors with hypermethylated phenotype were considered those with CIMP positive,
and microsatellite stable results.
DNA tumor methylation status. The DNA tumor methylation status in CIMP was
assessed by methylation-specific multiplex ligation-dependent probe amplification (MS-
MLPA) using the SALSA MLPA ME042 CIMP probemix (MRC-Holland, Amsterdam, The
Netherlands) according to the manufacturer’s protocol. This probemix contains 31 MS-MLPA
probes which detect the methylation status of promoter regions of the following eight genes:
CACNA1G, CDKN2A,CRABP1, IGF2, MLH1, NEUROG1,RUNX3 and SOCS1. An altered
methylation in these genes has been reported in the literature and has been used to test CIMP
status [9]. The dichotomization threshold to distinguish methylated versus non-methylated
samples was established at 20%. Tumors were considered as CIMP positive when at least five
genes showed methylation over the established threshold in at least one of their probes [10].
Microsatellite instability analysis. Colorectal tumor DNAs were tested for MSI using
multiplex-PCR for five mononucleotide quasimonomorphic markers (BAT25, BAT26, NR21,
NR24 and NR27) and molecular analysis of fragments through capillary electrophoresis as
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previously described by Buhard et al [11]. Tumors were classified as MSI when at least two of
the markers showed an altered peak pattern.
Qualitative analysis of EBV and CMV in normal and colorectal tumor tissues. Detec-
tion of EBV and CMV in normal colon and tumor tissues was approached by conventional
singleplex PCR in a 45-cycle reaction to improve the sensitivity of the assay [12]. PCR primers
and conditions are shown in S1 Table. All the DNAs were tested in triplicate, and positive and
negative DNA controls were included for each run. Analyses of TP53 and β-globin human
genes were tested in parallel as controls for each DNA. A GeneAmp PCR System 9700
(Applied Biosystems) was used for PCR reactions, and electrophoresis to visualize amplifica-
tion products in ethidium bromide-stained agarose gels. Positive results were considered when
at least two of the three PCR replicates rendered a visible amplicon band with the expected
size. To assess the specificity of the assay, 10 consecutive positive results for each virus were
sequenced forward and reverse with a 3130 Genetic Analyser (Applied Biosystems), and the
sequences’ results were aligned by BLASTn (http://blast.st-va.ncbi.nlm.nih.gov/Blast.cgi) for
verification.
Statistical analysis
The applied statistical tests were bilateral and significance was established at p< 0.05. The
baseline characteristics of patients are presented as relative frequencies and were compared
using χ2 tests or Fisher’s exact test if necessary for categorical variables. The normality of the
distribution of continuous variables was checked with the Shapiro–Wilk test, then they were
described as means and standard deviation (SD) or medians and interquartile ranges (IR) and
compared with the SG results using the Student’s t test or Mann–Whitney U test as appropri-
ate. We estimated odds ratios (ORs) and 95% confidence intervals (CI) using multivariable
adjusted logistic regression models. The models were controlled for potential confounders
based on published factors and those variables with p values < 0.20 in the bivariate analysis.
The statistical analysis was performed using the statistical software R 3.3.0 (R Foundation
for Statistical Computing, Vienna, Austria; http://www.r-project.org).
Results
Analytical validation of the method for quantitating SG indicated sensitivity and specificity of
100% with a limit detection of 10 copies of bacterial genomic DNA (data not shown). All 20
SG isolates used as positive controls were identified and good reproducibility between experi-
ments was achieved.
Overall, the median age of patients at diagnosis was 70 (range: 30–94) years and 95 (50%)
were women. Thirty-eight cases of proximal colon cancer (20%) and 118 of distal colon cancer
(62%) were observed. There were 42 (22%) cases at stage II and 48 (25%) at stage III. No data
for tumor location or staging were available for 34 and 100 patients, respectively.
Six of the 190 patients included (3.2%) were positive for SG. All the positive cases were
identified from tumor tissue samples, while none of the normal mucosa samples showed
detectable SG DNA (p = 0.03). No other significant association was found for SG. The results
of the bivariant analysis are shown in Table 1.
The average SG copy number was 7,018 (range 44–34,585). In four of the six SG positive
tumors, all three replicates were positive; while in the remaining two tumors only two of three
replicates were considered positive. The results for these two samples were confirmed in an
independent experiment.
The analysis of the molecular hallmarks of the tumors indicated that 9.5% of cases showed
MSI (18/190) and 22.1% were CIMP-positive (CIMPpos) (42/190). Based on these results, a
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primary molecular pathway classification of tumors was established: 72.1% were classified as
CIN (defined as CIMP negative (CIMPneg) and microsatellite-stable (MSS) tumors: 137/190);
9.5% as microsatellite unstable (MSI and any CIMP: 18/190); and 16.8% as CIMP (CIMPpos
and MSS tumors: 32/190).
Tumors with MSI were associated with a proximal colon location (MSI-proximal (MSI-P):
10; MSI-distal (MSI-D): 5 vs. MSS-P: 28; MSS-D: 113; p< 0.001), earlier stages (MSI-Stage II:
10; MSI-Stage III: 2 vs. MSS-Stage II: 32; MSS-Stage III: 46; p = 0.002) and hypermethylation
status (MSI-CIMPpos: 10; MSI-CIMPneg: 8 vs. MSS-CIMPpos: 32; MSS-CIMPneg: 108;
p = 0.001).
EBV was detected in 52.4% of cases (99/189). In 63 of these cases, EBV was found only in
tumor tissue; in 33 cases it was detected in both normal and tumor tissues, and in three cases it
Table 1. Clinicopathological, molecular and biological features of included patients stratified by Streptococcus gallolyticus infection.
Total patients
(n = 190)
n (%) of positive SG6 (3.2) n (%) of negative SG184 (96.8) *p-value
Gender 0.09
Male 5 (2.6) 90 (47.4)
Female 1 (0.5) 94 (49.5)
Age (mean ± SD) 67.6 (8.38) 70.1 (11.4) 0.43
Type of tissue (n = 380) 0.03
Normal 0 (0) 190 (50)
Tumoral 6 (1.6) 184 (48.4)
Tumour location 0.63
Proximal 2 (1.3) 36 (23.1)
Distal 4 (2.6) 114 (73.1)
Tumour stage 0.12
II 4 (4.4) 38 (42.2)
III 1 (1.1) 47 (52.2)
CIMP status 0.61
Positive 2 (1.1) 40 (21.4)
Negative 4 (2.1) 141 (75.4)
Microsatellite phenotype 0.42
MSI 0 (0) 18 (9.5)
MSS 6 (3.2) 166 (87.4)
Molecular carcinogenetic pathways 0.45
CIN 4 (2.1) 133 (71.1)
CIMP 2 (1.1) 30 (16)
MSI 0 (0) 18 (9.6)
CMV infection (n = 380) 0.72
Positive 1 (0.3) 44 (11.8)
Negative 5 (1.3) 324 (86.6)
EBV infection (n = 380) 0.01
Positive 5 (1.3) 127 (34)
Negative 1 (0.3) 241 (64.4)
SG: Streptococcus gallolyticus; SD: Standard deviation; CIMP: CpG island methylator phenotype (CIMP)-positive tumor; MSI: Microsatellite instability;
MSS: Microsatellite stability; CIN: Chromosomal instability; CMV: Cytomegalovirus; EBV: Epstein-Barr virus.
*P-values are from χ2 test (Fisher’s exact test if necessary) or Mann-Whitney U test comparing S. gallolyticus results with categorical or continuous
variables respectively.
https://doi.org/10.1371/journal.pone.0174305.t001
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was found only in normal tissues (p< 0.001). CMV was detected in 22.8% of cases (43/189)
and also was found significantly more often in tumor tissues than in normal tissue (43 tumor
vs. 2 normal tissue, p< 0.001). Overall, a significant level of coinfection of CMV and EBV was
found (p< 0.001). However, no association was observed when EBV–CMV coinfection was
stratified by tissue type (normal vs. tumor).
In the logistic regression model, the presence of SG was associated with EBV infection
(p = 0.042; OR: 9.49; 95% IC: 1.1–82.9) while the remaining variables were discarded in the
adjustment process. Details of the logistic regression are shown in S2 Table. A description of
the SG-positive cases identified in this study is shown in Table 2.
S3 Table shows the results for the analyzed variables for the whole series of cases.
Discussion
The present study describes new insights into the nature of SG infection and its association
with CRC. First, we developed a new quantitative method to assess bacterial load. Analytical
validation was reached with a very high sensitivity and specificity. Second, we found a 3.2%
prevalence of SG infection in our unselected cohort of CRC cases. No previous reports relating
to SG infection have been published for unselected cohorts of patients. Third, to further char-
acterize the nature of SG infection we performed an association study with clinical, pathologi-
cal, molecular and other biological variables. Despite a low prevalence of SG in this study, we
were able to define a specific association with tumor tissue and with coinfection with EBV.
The course of evolution of CRC depends on a combination of intrinsic and extrinsic factors.
Therefore, the (epi)genetic background involving the main molecular factors that define differ-
ent oncogenic pathways, together with lifestyle and microenvironmental (gut microbiota) fac-
tors and tumor treatment in combination with immune surveillance and immune responses,
identify a complex combination of factors that defines the selective pressures that will deter-
mine the course of the disease [13].
To our knowledge, this is the first report in which SG in CRC patients is explored in rela-
tion to the molecular pathways of oncogenesis and concomitant viral infections. We hypothe-
sized that this approach could be useful for providing information about the potential causal
role of SG infection in tumorigenesis and the mechanisms involved.
Our results show a low prevalence (3.2%) of SG infection in patients with CRC compared
with that reported in other studies [8]. Abdulamir et al. [14] reported a higher prevalence of
SG in CRC patients: up to 49% in tumor tissue and 36% in the corresponding normal colonic
mucosa. However, in that article, the authors focused on the study of CRC and normal tissues
from a selected population with a history of SG bacteremia, which is a quite different scenario
to the unselected series of CRC patients included in our study. Moreover, differences in the
Table 2. Description of the Streptococcus gallolyticus-positive cases identified in the study.
Case Gender Age EBV co-infection CMV co-infection CIMP status Tumour location Stage Microsatellite phenotype Mean Qty
1 Male 62 + - P Distal III MSS 840
2 Male 63 - - P Proximal II MSS 149
3 Male 83 + + N Distal II MSS 1,390
4 Female 72 + - N Distal - MSS 34,585
5 Male 63 + - N Distal II MSS 5,102
6 Male 63 + - N Proximal II MSS 44
EBV: Epstein-Barr virus; CMV: Cytomegalovirus; “P” indicates CpG island methylator phenotype (CIMP)-positive tumour; “N” indicates CpG island
methylator phenotype (CIMP)-negative tumour; MSS: Microsatellite stability; Mean Qty: Mean of S. gallolyticus number of copies.
https://doi.org/10.1371/journal.pone.0174305.t002
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methodological aspects related to the detection of SG may contribute to the apparent discrep-
ancy in the results.
The quantitative analysis of SG identified a broad range of bacterial loads (44–34,585 cop-
ies). For subsequent association analysis we dichotomized the results as SG-positive and SG-
negative. It is very likely that a putative biological effect of SG on the tumor could be influ-
enced by the bacterial load. We used 50 ng of DNA isolated from tumor tissues to establish the
bacterial load, which represents a total of 8,000–10,000 tumor cells. Thus, the estimated ratio
of copies of SG/tumor cell ranged from 5:1,000 to 4:1. It would be interesting to explore the
pathological and clinical significance of the SG/tumor cell ratio in a larger series to obtain a
more precise picture.
Despite the low prevalence of SG infection found in this unselected series of CRC patients,
our results suggest that SG may play a role in CRC carcinogenesis and/or tumor progression
because of the lack of detection of the bacterium in the normal colon mucosa. Similarly, our
findings that EBV and CMV infections were preferentially found in tumor tissues may reflect
their potential role in CRC oncogenesis. These results are consistent with those previously
reported by Salyakina and Tsinoremas [7]. EBV is potentially causal in gastrointestinal cancer
because it encodes oncoproteins and is able to transform human cells [15], while the oncogenic
nature of CMV is still debatable [5].
MSI is a very well established marker used in clinical settings as diagnostic of Lynch syn-
drome, a good prognostic factor, and even as a predictor of treatment response [16]. In con-
trast, assessment of CIMP status is not conventional and is only used in a research context.
The prognostic value of CIMP positivity is not known. Most studies show a worse prognosis
for CIMPpos CRC, although adjuvant treatment seems to be more efficient in these tumors
[17]. The methodology we used and the criteria we used to define CIMPpos tumors are restric-
tive enough to provide high specificity [18]. The frequencies of MSI and CIMP and the path-
way distribution were concordant with those reported in the literature [2, 3]. Furthermore, the
results obtained in this cohort support the well-established association of MSI tumors with a
proximal colon location, earlier stages and hypermethylation status [19].
Despite the low number of cases positive for SG, we were able to identify its strong association
with EBV coinfection and its presence specifically in tumor tissue, factors which have not been
described previously. However, we still do not have enough information to establish whether SG
infection is a cause (with an adjuvant or oncomodulator effect) or a consequence of the carcino-
genic process. Further studies are needed to establish the association of SG with specific clinico-
pathological and molecular profiles of tumors to define its potential role in oncogenesis.
We acknowledge the limitations of this study. The limited sample size used in this work
and the considerable amount of missing clinical and pathological data made it difficult to
achieve results with high statistical power (potency of 72.5%). Consequently, we must be cau-
tious with the interpretation of the results and consider them only as a proof of concept.
Nevertheless, it is important to note that the prevalence data provided by this study for SG
infection in the tumors of an unselected cohort of CRC patients will be very useful in the
design of future studies, and will make it possible to estimate the sample size needed to assess
precise objectives.
Conclusion
Our results show a low prevalence of SG infection in a cohort of unselected CRC patients and
an association of positive SG infection with tumor tissue and EBV coinfection. Further studies
will be needed to definitively assess the prevalence of SG in CRC and the associated clinico-
pathological and molecular profiles.
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